Research by the World Health Organization has shown that“Physically, it is much more difficult to stop the production of millions of sperm per day for men than to prevent women from releasing an egg every month.” In the contraceptive drugs market, contraceptive drugs for women account for 90%, and is gradually becoming just as accepted in China as it is in most other parts of the world.
Monday, November 09, 2020 – 06:45am Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005539/en/ NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE)– Pfizer Inc. (NYSE: ...
Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly. The most commonly used drugs to slow the progression of the disease is Roche’s Lucentis and Regeneron’s Eylea. These drugs are injected into the eye which, needless to say, leads to more inconvenience.
An analysis of Bayer's XANTUS programme revealed the safety profile of the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in clinical practice.
In a major setback for Eisai and Merck & Co, the FDA has stalled the roll-out of Lenvima as a treatment for earlier untreated liver cancer patients. Big things were expected by Merck & Co when Eisai’s Lenvima was scheduled to be launched in March. Merck has agreed to shell out USD 5.8 billion on half of the liver cancer’s drug sales.
Though the US stands first in the race in terms of sales and growth, it is highly believed that China would reach the peak in the pharma market by 2022. At present, since there has been a decrease in public health funding, there has been a slight fall in pharmerging countries like Brazil, Russia, India and China (BRIC). But it is believed that the condition of these pharmerging countries will improve in the next five years [1].
Cedars-Sinai will be testing a digital pain-reduction kit, which includes VR glasses and mHealth wearables, to see if mobile health technology can replace opioids for people recovering from workplace injuries.
The FDA has ordered the recall of a mHealth app that helps people with diabetes determine how much insulin they should inject. The issue points to the continuing challenge of verifying the accuracy of digital health devices and drug dosage apps.
Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. News of Lundberg’s departure emerged on the same day Celgene revealed it has sold another chunk of its once-double-digit stake in the CRISPR/Cas9 gene editing startup.
London-based startup accompanying U.K. Prime Minister on trade mission
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.